Short answer
CYTOKINETICS INC (CYTK) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $48M (up 2356.5% year over year) with net income of −$190M.
Q3 2026 key financials · XBRL
- Revenue
- $48M
- +2356.5% YoY · +66.1% QoQ
- Net income
- −$190M
- +37.9% YoY · +4.4% QoQ
- Operating margin
- -351.3%
- EPS (diluted)
- −$1.35
- +47.1% YoY · +10.0% QoQ
Source: XBRL data from the CYTOKINETICS INC (CYTK) Q3 2026 10-Q on SEC EDGAR. USD.
CYTOKINETICS INC Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $47.6M, up $45.6M YoY, driven by MYQORZO product revenue of $44.5M
- Q3 operating expenses $214.6M, up $46.0M YoY, including SG&A of $113.1M
- Best-performing product line: MYQORZO U.S. revenue $43.1M, Europe $1.4M
- Cash, cash equivalents and securities $1.58B, up from $1.22B at December 31, 2025
- Nine-month operating cash outflow $429.3M, financing inflow $805.4M including $760.1M public-offering proceeds
Risk Factors
- New regulatory risk: August 2026 ACACIA-HCM results may not support aficamten approval for nHCM
- Most material update: Planned supplemental NDA submission in fourth quarter 2026 after positive dual primary endpoints
- FDA review risk: Left ventricular ejection fraction below 50% occurred more frequently with aficamten
- Competitive risk: Camzyos failed both dual primary endpoints in ODYSSEY-HCM for nHCM
- Commercial risk: Delayed or limited approval could prevent nHCM commercialization on the anticipated timeline
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other CYTOKINETICS INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.